Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Asset Writedowns and Impairment (2017 - 2025)

Coherus Oncology's Asset Writedowns and Impairment history spans 8 years, with the latest figure at $12.5 million for Q4 2025.

  • For Q4 2025, Asset Writedowns and Impairment rose 6.79% year-over-year to $12.5 million; the TTM value through Dec 2025 reached $24.6 million, up 74.05%, while the annual FY2025 figure was $14.1 million, 0.3% changed from the prior year.
  • Asset Writedowns and Impairment for Q4 2025 was $12.5 million at Coherus Oncology, up from $500000.0 in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $48.2 million in Q4 2023 and bottomed at -$4.3 million in Q2 2024.
  • The 4-year median for Asset Writedowns and Impairment is $2.4 million (2023), against an average of $8.0 million.
  • The largest YoY upside for Asset Writedowns and Impairment was 109.81% in 2024 against a maximum downside of 1144.67% in 2024.
  • A 4-year view of Asset Writedowns and Impairment shows it stood at -$59000.0 in 2021, then skyrocketed by 81847.46% to $48.2 million in 2023, then tumbled by 75.82% to $11.7 million in 2024, then rose by 6.79% to $12.5 million in 2025.
  • Per Business Quant, the three most recent readings for CHRS's Asset Writedowns and Impairment are $12.5 million (Q4 2025), $500000.0 (Q3 2025), and $11.7 million (Q4 2024).